

**IN THE MATTER OF**  
**FRANCES U. DIMONYE**

**Respondent**

**License Number: 30087**

**BEFORE THE MARYLAND**  
**STATE BOARD OF PHARMACY**

**Case Number: 26-311**

---

**ORDER FOR SUMMARY SUSPENSION OF**  
**LICENSE TO PRACTICE PHARMACY**

The Maryland State Board of Pharmacy (the “Board”) hereby **SUMMARILY SUSPENDS** the license of **FRANCES U. DIMONYE** (the “Respondent”), License Number 30087, to practice pharmacy in the State of Maryland. The Board takes such action pursuant to its authority under Md. Code Ann., State Government (“State Gov’t”) § 10-226(c), and Md. Code Regs. (“COMAR”) 10.34.01.12, having concluded that the public health, safety, or welfare imperatively requires emergency action.

**INVESTIGATIVE FINDINGS<sup>1</sup>**

**I. BACKGROUND**

1. At all times relevant, the Respondent was licensed to practice pharmacy in the State of Maryland under License Number 30087. The Respondent was initially licensed to practice pharmacy in Maryland on October 9, 2024. The Respondent’s license expires on April 20, 2028, subject to renewal.

---

<sup>1</sup> The statements regarding the Respondent’s conduct are intended to provide the Respondent with reasonable notice of the basis for the Board’s action. They are not intended as, and do not necessarily represent, a complete description of the evidence to be offered against the Respondent in this matter.

2. At all times relevant, the Respondent was employed as a pharmacist with a national pharmacy chain (the “Pharmacy”)<sup>2</sup> at its location in Pikesville, Maryland.

3. On or about March 30, 2026, the Board received a complaint (the “Complaint”) from a government agency regarding a theft of Schedule II drugs at a retail pharmacy in Maryland. The Complaint included a police report from the Baltimore County Police Department regarding the theft listing the Respondent as a suspect.

4. After receiving the Complaint, the Board initiated an investigation of the Respondent under case number 26-311.

## **II. BOARD INVESTIGATION**

5. The Board’s investigation revealed that in late February 2026, the pharmacy manager (the “Pharmacy Manager”) at the Pharmacy was conducting an inventory of drugs when he found 23 units of oxycodone missing. As a result, the Pharmacy Manager began conducting daily inventory of drugs on a daily basis.

6. On or about March 11, 2026, the Pharmacy Manager conducted an inventory of the oxycodone medications and found the inventory to be accurate. The next day on March 12, 2026, the Pharmacy Manager was off from work, and the Respondent worked at the Pharmacy that day.

---

<sup>2</sup> For confidentiality and privacy purposes, the names of individuals and facilities involved in this case are not disclosed in this document. The Respondent may obtain the names of all individuals referenced in this document by contacting the administrative prosecutor.

7. The Pharmacy Manager returned to work on or about March 13, 2026, and when he conducted an inventory of oxycodone medications that day, he found 95 units of oxycodone to be missing.

8. The Pharmacy Manager immediately notified his supervisor, and they reviewed the Pharmacy's surveillance video for March 12, 2026. From the surveillance video, they observed the Respondent removing a bottle of pills, suspected to be oxycodone, from a blue tote and concealing the bottle in the left pocket of her white lab coat at or around 5:30 p.m.

9. On or about March 17, 2026, an Asset Protection Manager and the Store Manager interviewed the Respondent. During the interview, the Respondent acknowledged that she was the only pharmacist who had access to the safe that stored Schedule II controlled dangerous substances on March 12, 2026. Moreover, the Respondent stated that she could not take oxycodone or Adderall because she could not tolerate them, even though neither the Asset Protection Manager nor the Store Manager mentioned the drug in question.

10. On or about March 26, 2026, the Respondent was terminated by the Pharmacy for gross misconduct.

### **CONCLUSIONS OF LAW**

Based on the foregoing investigative findings, the Board concludes, as a matter of law, that the public health, safety, or welfare imperatively requires emergency action in

this case, pursuant to Md. Code Ann., State Gov't § 10-226(c)(2) and COMAR 10.34.01.12.

**ORDER**

Based on the foregoing Investigative Findings and Conclusions of Law, by a majority vote of the Board, it is hereby:

**ORDERED** that pursuant to the authority vested in the Board by Md. Code Ann., State Gov't § 10-226(c)(2), the license issued to the Respondent, **FRANCES U. DIMONYE**, License Number 30087, to practice pharmacy in the State of Maryland is hereby **SUMMARILY SUSPENDED**; and it is further

**ORDERED** that the Respondent is prohibited from practicing pharmacy in the State of Maryland; and it is further

**ORDERED** that the Respondent shall immediately surrender her Maryland pharmacy license and any renewal or wall certificates to the Board; and it is further

**ORDERED** that the Respondent has the opportunity to appear before the Board for a post-deprivation show cause hearing. A request for a post-deprivation show cause hearing must be made to the Board in writing **WITHIN THIRTY (30) DAYS**; and it is further

**ORDERED** that if the Respondent does not request a post-deprivation show cause hearing in writing within thirty (30) days, or if the Respondent requests a post-deprivation show cause hearing but fails to appear when scheduled, the Respondent's registration will remain **SUSPENDED**; and it is further

**ORDERED** that this **ORDER FOR SUMMARY SUSPENSION** is a **PUBLIC DOCUMENT** pursuant to Md. Code Ann., Gen. Prov. §§ 4-101 *et seq.*

8-7-26  
Date

Deena Speights-Napata  
Deena Speights-Napata, M.A  
Executive Director  
Maryland State Board of Pharmacy